Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The six accepted presentations highlight clinical progress across Eikon’s pipeline.
-
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...
-
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report...
-
Leafwell Advances Medical Cannabis as Clinically Validated Solution for Cancer-Related Symptoms and Chronic Pain, Supports Employer-Sponsored Mental Health
-
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying
-
After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study
-
OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the Company has...
-
Garching / Munich, May 19, 2026 –– ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that dosimetry data from its Phase 3 COMPETE trial will be...
-
Meet Avance Clinical's Oncology Center of Excellence expert team at ASCO Annual Meeting in Chicago, held 29 May – 2 June 2026.